Guidance, NICE advice and quality standards in development | Guidance

Showing 1 to 10 of 427

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]	Technology appraisal guidance	12 February 2025
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]	Technology appraisal guidance	TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533	Technology appraisal guidance	TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]	Technology appraisal guidance	TBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	20 August 2025
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339	Technology appraisal guidance	2 July 2025
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	TBC